Cuberas-Borrós, Gemma http://orcid.org/0000-0001-5276-8212
Roca, Isabel
Castell-Conesa, Joan
Núñez, Laura
Boada, Mercè
López, Oscar L.
Grifols, Carlota
Barceló, Miquel
Pareto, Deborah
Páez, Antonio
Funding for this research was provided by:
Grifols S.A.
Article History
Received: 21 February 2022
Accepted: 14 July 2022
First Online: 22 July 2022
Declarations
:
: This study was conducted in compliance all applicable regulatory guidelines and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP). Institutional Review Boards (IRBs) or Ethics Committees from the sites and the Health Authorities from the countries where the study was performed approved the protocol, the informed consent form, and the patient information sheets.
: Each patient and caregiver, family member, or legal representative provided informed consent prior to enrollment.
: Not applicable.
: MBo has been a consultant for Araclon, Avid, Bayer, Elan, Grifols, Janssen/Pfizer, Lilly, Neuroptix, Nutricia, Roche, Sanofi, Biogen, and Servier; and received fees for lectures and funds for research from Araclon, Esteve, Grifols, Janssen, Novartis, Nutricia, Piramal, Pfizer-Wyett, Roche, and Servier. OLL has been a consultant for Grifols and Lundbeck. LN, MBa, CG, and AP are full-time employees of Grifols.